Rhinitis, allergic, seasonal; Ioratadine; antihistamine; fluticasone propionate
aqueous nasal spray [non-MeSH].
Teva Pharmaceutical Industries (NYSE:TEVA)(TASE:TEVA) revealed on Tuesday that the US Food and Drug Administration (FDA) has accepted for review its new drug applications (NDAs) for two products, fluticasone propionate/salmeterol and fluticasone propionate
, for adolescent and adult patients with asthma, a chronic (long term) disease usually characterized by airway inflammation and narrowing of the airways, which can vary over time.
At all clinic visits, fluticasone propionate
compared with placebo was associated with significant (P[less than].05) improvement in pulmonary function indexed by forced expiratory volume in 1 second [(FEV.sub.1]) as well as fewer night awakenings and less use of rescue albuterol.
The companies added Flonase (fluticasone propionate
nasal spray USP, 50 mcg per spray) is indicated for the temporary relief of hay fever or other upper respiratory allergies in adult and pediatric patients four years of age and older.
The researchers used a database representing 20 health plans with more than 5 million patients to identify 4,184 patients who started fluticasone propionate
monotherapy for asthma and 3,846 who started montelukast monotherapy between January 1999 and June 2000.
A dose-ranging study of fluticasone propionate
aqueous nasal spray for seasonal allergic rhinitis assessed by symptoms, rhinomanometry, and nasal cytology.
The company said fluticasone propionate
100, 250, 500 mcg and salmeterol 50 mcg inhalation powder is the generic version of GlaxoSmithKline's Advair Diskus, which is indicated for treating asthma and the maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD).
Pharmaceutical company Mylan NV (NASDAQ:MYL) (TASE:MYL) announced on Monday that it has submitted its abbreviated new drug application (ANDA) for fluticasone propionate
100, 250, 500 mcg and salmeterol 50 mcg inhalation powder to the US Food and Drug Administration (FDA) in December 2015.
The primary outcome was a reduction in inhaled fluticasone propionate
M2 PHARMA-June 29, 2016-Teva Pharmaceutical's NDAs for fluticasone propionate/salmeterol RespiClick and fluticasone propionate
RespiClick accepted by the US FDA for review